65,437 trials
Hypercholesterolaemia
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate — 733; 554; 850; 570 hr*nmol/Liter
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Dropout — 3; 2; 5; 2 Participants
Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Event-free Survival Rate (EFS) — 21.3 Months
Major Depressive Disorder
Primary: Evaluate Comfort of TMS Treatment — 29.9; 29.3 VAS score on a scale
Depression · Depressive Disorder · Depressive Symptoms
Primary: Montgomery Asberg Depression Rating Scale (MADRS) — -12.8; -12.7 units on a scale
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Incidence of Adverse Events (Phase I) — 3; 3; 6 Participants
Bladder Cancer
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 2; 2; 1; 3 Participants
Prostate Cancer
Primary: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab — -8.28 Percentage change Phospho-IGF-1R+ cells
Atopic Asthma
Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants
Healthy Adults
Primary: Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35) — 27.00; 31.25; 27.00; 27.00 copies/ng DNA — p=<0.0001
Anterior Cruciate Ligament Tear · Anterior Cruciate Ligament Rupture
Primary: Change in Synovial Interleukin (IL) -1 Receptor Antagonist Concentration — 13.8; 16; 9.9; 7.5 pg/ml
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
Suicide
Primary: Suicidal Ideation and Behavior — 2.625; 2.34375; 1.37931; 1.064516 Mean Units on the CSSRS SI scale
Interstitial Cystitis/Painful Bladder Syndrome · Myofascial Pelvic Pain
Primary: Total Score on Genitourinary Pain Index (GUPI) Scale — 24.4; 22.2; 2.35; 29.25 score on a scale